Generic Drug Name:



Generic Drug Name:

Folic acid

|Drug Classification:

Water soluble vitamins

|Location of metabolism/excretion:

Converted by the liver to its active metabolite. Excess amounts are excreted unchanged by the kidneys. |Nursing Implications/Assessment:

▪ Assess patient for signs of megaloblastic anemia (fatigue, weakness, dyspnea) before and periodically throughout therapy

▪ Do not confuse with folinic acid

▪ Antacids should be given at least 2 hours after folic acid; folic acid should be given 2 hours before or 4-6 hours after. | |

|Brand/Trade Names: |Half/Life: | | |

|(List 1-2 most common) |Unknown | | |

|Vitamin B6 | | | |

|Vitamin B12 | | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Given during pregnancy to promote |Uncorrected pernicious aplastic or normocytic |Onset: 30-60 min. |Encourage patient to comply with diet recommendations of health care professional |

|normal fetal development |anemias (neurological damage will progress |Peak: 1 hour |Foods high in folic acid include vegetables, fruits, and organ meats, heat destroys |

| |despite correction of hematological |Duration: unknown |folic acid in foods |

| |abnormalities). Preparations containing benzyl| |May cause urine more intensely yellow |

| |alcohol should not be used in newborns. | |Notify health care professional if rash occurs, may indicate hypersensitivity |

| | | | |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Required for protein synthesis and red|Rashes, irritability, difficulty sleeping, | |Maintain appropriate folic acid levels so the fetus develops normally |

|blood cell function. Stimulates the |malaise, confusion, fever |PO (adults): 1 mg/day initial dosage | |

|production of red blood cells, white | |then 0.5 mg/day maintenance dose | |

|blood cells, and platelets. Necessary | | | |

|for normal fetal development. | |Patient: 1 mg tab orally once a day | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Drug-Drug: Absorption is decreased by | |Monitor plasma folic acid levels, hemoglobin, hematocrit, and reticulocyte count before |

|Restoration and maintenance of normal |sulfonamides, antacids, and cholestyramine. | |and during therapy |

|hematopoiesis. |Requirements are increased by estrogens, | |May cause a decrease in serum concentrations of other B complex vitamins when given in |

| |phenytoin, phenobarbital, primidone, | |high continuous doses |

| |carbamazepine or corticosteroids. | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Magnesium sulfate |Mineral and electrolyte |Excreted primarily by the kidneys |Monitor fetus/newborn for hypotension, hyporeflexia, and respiratory depression |

| |replacements/supplements | |Monitor intake and output ratios. Urine output should be maintained at a level of at |

| | | |least 100 ml/4hr. |

| | | |Monitor pulse, blood pressure, respirations |

| | | |Monitor neurological status before and throughout therapy. Patellar reflex (knee jerk) |

| | | |should be tested before each dose. If response is absent, no additional dose should be |

| | | |administered until positive response. |

|Brand/Trade Names: |Half/Life: | | |

|Magnesium |Unknown | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Preterm labor |Hypermagnesemia. Hypocalcemia. Anuria. Heart |IV: |Explain purpose of medication to patient and family |

| |block. Active labor or within 2 hours of |Onset: immediate | |

| |delivery (unless used for preterm labor) |Peak: unknown | |

| | |Duration: 30 min | |

| | | | |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Stops contractions of the uterus and |Drowsiness, decreased respiratory rate, | |Preterm labor contractions controlled and slowed or stopped. |

|prevents preterm labor. Essential for |arrhythmias, bradycardia, hypotension, |Patient: Sodium chloride 0.9% 500 mL | |

|activity of many enzymes. Plays an |diarrhea, muscle weakness, sweating, flushing,|with Magnesium Sulfate 50% 40 gm | |

|important role in neurotransmission |hypothermia | | |

|and muscular excitability. | |Total equaling 580 mL | |

| | | | |

| | |IV: 35 mL/hr | |

|Therapeutic Effects: |Interactions: | |Labs to monitor (if applicable): |

|Replacement in deficiency states. |Drug-Drug: Potentiate calcium channel blockers| |Serum magnesium levels and renal function should be monitored periodically throughout |

|Resolution of eclampsia. |and neuromuscular blocking agents. | |administration of parenteral magnesium sulfate |

| | | | |

| | | | |

| | | | |

| | | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Ferrous fumarate |Antianemics, iron supplements |Mostly recycled, small daily losses |Assess bowel function for constipation or diarrhea. |

| | |occurring via desquamation, sweat, |Assess patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, |

| | |urine, and bile |wheezing). Notify physician immediately if these occur. Keep epinephrine and |

| | | |resuscitation equipment close. |

|Brand/Trade Names: |Half/Life: | | |

|Prenatal vitamin |Unknown | | |

|Iron Supplement | | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Prevention/treatment of |Primary hemochromatosis. Hemolytic anemias and|Onset: 4 days |Encourage patient to comply with medication regimen. |

|iron-deficiency anemia |other anemias not due to iron deficiency. Some|Peak: 7-10 days | |

| |products contain alcohol, tartrazine, or |Duration: 2-4 months | |

| |sulfites, and should be avoided in patients | | |

| |with known intolerance or hypersensitivity. | | |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|An essential mineral found in |Constipation, dark stools, diarrhea, | |Increase in hemoglobin, hematocrit, and plasma iron levels |

|hemoglobin, myoglobin, and many |epigastric pain, GI bleeding |Patient: one 1 mg tablet orally once a | |

|enzymes. | |day with breakfast | |

|Therapeutic Effects: |Interactions: | |Labs to monitor (if applicable): |

|Prevention/treatment of iron |Drug-Drug: Tetracycline and antacids increase | |Monitor hemoglobin, hematocrit, and reticulocyte values |

|deficiency |oral absorption of iron by forming insoluble | | |

| |compounds. Oral iron supplements decrease | | |

| |absorption of tetracyclines, fluoroquinolones,| | |

| |and penicillamine (simultaneous administration| | |

| |should be avoided) | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Docusate |Laxatives, stool softeners |Amounts absorbed after oral |Assess for abdominal distention, presence of bowel sounds, and usual pattern of bowel |

| | |administration are eliminated in bile |function |

| | | |Assess color, consistency, and amount of stool produced |

|Brand/Trade Names: |Half/Life: | | |

|Colace |Unknown | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Prevention of constipation, in |Hypersensitivity, abdominal pain, nausea, or |Onset: 24-48 hours (up to 3-5 |Advise patients that laxatives should be used only for a short-term therapy. Long-term |

|patients that should avoid straining |vomiting, especially when associated with |days) |therapy may cause electrolyte imbalances and dependence |

| |fever or other signs of an acute abdomen |Peak: unknown |Encourage patient to increase fluid intake (6-8 full glasses/dry) and increasing |

| | |Duration: unknown |motility. Normal bowel habits may vary from 3 times/day to 3 times/week |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Promotes incorporation of water into |Throat irritation, mild cramps, rashes | |A soft, formed bowel movement, usually within 24-48 hours. Therapy may take 3-5 days for|

|stool, resulting in softer fecal mass.| |PO (adults) 50-500 mg once daily |results. |

|May also promote electrolyte and water| | | |

|secretion into the colon. | |Patient: 100 mg twice a day | |

|Therapeutic Effects: |Interactions: | |Labs to monitor (if applicable): |

|Softening and passage of stool |No significant interactions | |No labs to monitor |

| | | | |

| | | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Promethazine |Antiemetics |Metabolized by the liver |Monitor blood pressure, pulse and respiratory rate frequently |

| | | |If used for sedation, assess for level of sedation after administration |

| | | |Monitor patient for onset of extrapyramidal side effects (restlessness, muscle spasms, |

| | | |twisting motions, mask-like face, rigidity, tremors, drooling, shuffling gait, |

| | | |dysphasia) |

|Brand/Trade Names: |Half/Life: | | |

|Phenergan |Unknown | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Treatment and prevention of nausea and|Hypersensitivity. Comatose patients. Prostatic|Onset: 20 min. |May cause drowsiness |

|vomiting. Adjunct to anesthesia and |hypertrophy Bladder neck obstruction. Some |Peak: unknown |Advise patient that frequent mouth rinses, good oral hygiene, and sugarless gum may |

|analgesia. |products contain alcohol or bisulfites and |Duration: 4-12 hours |decrease dry mouth |

| |should be avoided in patients with known | |Advise patient to change position slowly to minimize orthostatic hypotension |

| |intolerance. Narrow angle glaucoma. | |Notify health care professional if sore throat, fever, jaundice, or uncontrolled |

| | | |movements |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Possesses significant anticholinergic |Neuroleptic malignant syndrome, confusion, | |Relief from nausea and vomiting |

|activity. Produces CNS depression by |disorientation, sedation, dizziness, fatigue, |IV (adults): 10-25 mg q 4 hours as | |

|indirectly decreased stimulation of |insomnia, bradycardia, hypertension, |needed | |

|the CNS reticular system. |hypotension, tachycardia, constipation, dry | | |

| |mouth, rashes |Patient: IVP as needed every 4 hours. | |

| | |Dilute with 10 ml normal saline, push | |

| | |over at least 2 minutes. Maximum IVP | |

| | |dose = 12.5 mg | |

| | | | |

| | |12.5 mg/ 0.5 ml | |

|Therapeutic Effects: |Interactions: | |Labs to monitor (if applicable): |

|Diminished nausea or vomiting |Addictive anticholinergic effects with other | |CBC should be evaluated periodically during chronic therapy, blood dyscrasias may occur |

| |drugs possessing anticholinergic properties, | |May cause increased serum glucose |

| |including other antihistamines, | |May cause false-positive or false-negative pregnancy test results |

| |antidepressants, atropine, haloperidol | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Diphenhydramine |Allergy, cold, cough remedies, antihistamines,|95% metabolized by the liver |Diphendydramine has multiple uses. Determine why the medication was ordered and assess |

| |antitussives | |symptoms that apply to the individual patient |

| | | |Assess sleep patterns |

|Brand/Trade Names: |Half/Life: | | |

|Benadryl |2.4-7 hours | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Mild nighttime sedation |Hypersensitivity. Acute attacks of asthma. |Onset: 15-60 minutes |Instruct patient to take medication as directed |

| |Lactation. Known alcohol intolerance (some |Peak: 2-4 hours |May cause drowsiness |

| |liquid products) |Duration: 4-8 hours |Caution patient to avoid use of alcohol and other CNS depressants with this medication |

| | | |Inform patient that this drug may cause dry mouth |

| | | | |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Antagonizes the effects of histamine |Drowsiness, dizziness, headache, paradoxical | |Sedation when used as a sedative/hypnotic. |

|at H receptor sites, does not bind to |excitation, blurred vision, hypotension, |PO (adults): 50 mg tab, 20-30 minutes | |

|or inactivate histamine. Significant |anorexia, dry mouth, constipation, nausea, |before bedtime | |

|CNS depressant and anticholinergic |urinary retention, chest tightness, wheezing | | |

|properties. | |Patient: 50 mg orally at bedtime when | |

| | |needed | |

|Therapeutic Effects: |Interactions: | |Labs to monitor (if applicable): |

|Decreased symptoms of histamine |Drug-Drug: increase risk of CNS depression | |If used for allergy, Diphenhydramine may decrease skin response to allergy test. |

|excess. Relief of acute dystonic |with other antihistamines, alcohol, opioid | |Discontinue 4 days before skin testing. |

|reactions. Prevention of motion |analgesics, and sedative/ hypnotics. | | |

|sickness. Suppression of cough. | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Magnesium hydroxide |Mineral and electrolyte |Excreted primarily by the kidneys |Assess patient for abdominal distention, presence of bowel sounds, and usual pattern of |

| |replacement/supplements, laxatives, salines | |bowel function |

| | | |Assess color, consistency, and amount of stool produced |

| | | |Assess for heartburn and indigestion as well as location, duration, character, and |

| | | |precipitating factors of gastric pain |

|Brand/Trade Names: |Half/Life: | | |

|Milk of Magnesia |Unknown | | |

| | | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Treatment/prevention of |Hypermagnesemia. Hypocalcemia. Anuria. Heart |Onset: 3-6 hours |Advise patients not to take this medication within 2 hours of taking other medications |

|hypomagnesemia. As laxative, bowel |block. Active labor or within 2 hour of |Peak: unknown |Advise patients that laxatives should be used only for short-term therapy. Long-term |

|evacuate in preparation for |delivery (unless used for preterm labor) |Duration: unknown |therapy may cause electrolyte imbalance and dependence |

|surgical/radiographic procedures. Milk| | |Advise patient to notify health care professionals if unrelieved constipation, rectal |

|of Magnesia has also been used as an | | |bleeding, or symptoms of electrolyte imbalance |

|antacid. | | | |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Essential for the activity of many |Diarrhea, flushing, sweating | |Relief of gastric pain and irrigation |

|enzymes. Plays and important role in | |PO (adults): 30-60 ml single or divided|Passage of a soft, formed bowel movement, usually within 3-6 hours |

|neurotransmission and muscular | |dose or 10-20 ml as concentrate |Prevention and treatment of magnesium deficiency |

|excitability. They are osmotically | | | |

|active in GI tract, drawing water into| |Patient: 10 ml oral as needed | |

|the lumen and causing peristalsis | | | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Drug-Drug: Potentiates neuromuscular blocking | |No labs to monitor |

|Replacement in deficiency states. |agents. May decrease absorption of | | |

|Evacuation of the colon. |fluoroquinolones, nitrofurantoin, and | | |

| |tetracyclines, penicillamine | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Betamethasone sodium phosphate IM |Antiasthmatics, corticosteroids |All are metabolized mostly by the |Assess involved system before and periodically during therapy |

| | |liver. |Monitor intake and output ratios and daily weights. |

| | | |Observe patient for peripheral edema, steady weight gain, rales/crackles, or dyspnea. |

|Brand/Trade Names: |Half/Life: | | |

|Celestone |3-5 hours (plasma), 36-54 hours (tissue), | | |

| |adrenal suppression lasts 3.25 days | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: Onset: rapid |Key Patient Teaching Points: |

|Short-term administration to high-risk|Active untreated infection. Lactation. Known | |Instruct patient on correct technique of medication administration |

|mothers before delivery to prevent |alcohol, bisulfite, or tartrazine |Peak: unknown |Drugs cause immunosuppression and may mask symptoms of infection |

|respiratory distress syndrome in the |hypersensitivity or intolerance. |Duration: unknown |Instruct patient to inform health care professional promptly if severe abdominal pain or|

|newborn. |Administration of live virus vaccines. | |tarry stools occur |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Suppress inflammation and the normal |Depression, euphoria, hypertension, peptic | |Suppression of the inflammatory and immune responses in autoimmune disorders, allergic |

|immune response. All agents have |ulceration, anorexia, nausea, acne, decreased |IM (adults): up to 9 mg of |reactions, and neoplasms |

|numerous intense metabolic effects. |wound healing, ecchymoses, fragility, |betamethasone sodium phosphate or 0.5-9| |

| |hirsutism, petechiae, thromoboembolism, |mg IM as betamethasone sodium | |

| |osteoporosis |phosphate/acetate suspension | |

| | | | |

| | |Patient: IM every 24 hours, infuse over| |

| | |24 hours. Dose: 6 mg/ml up to 12 mg/ 2 | |

| | |ml | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Drug-Drug: increases risk of hypokalemia with | |Monitor serum electrolytes and glucose. May cause hyperglycemia, especially in persons |

|Suppression of inflammation and |thiazide and loop diuretics, amphotericin B, | |with diabetes. |

|modification of normal immune |piperacillin, or ticarcillin. Hormonal | |May increase serum cholesterol and lipid values |

|response. |contraceptives may decrease metabolism. | | |

| |Drug-Food: Grapefruit juice increase serum | | |

| |levels | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Morphine |Opioid analgesics, opioid agonists |Mostly metabolized by the liver |Assess level of consciousness, blood pressure, pulse, and respirations before and |

| | | |periodically during administration. If respiratory rate is less than 10/min, assess |

| | | |level of sedation. Physical stimulation may be sufficient to prevent significant |

| | | |hypoventilation. Subsequent doses may need to be decreased by 25-50%. Initial drowsiness|

| | | |will diminish with continued use. |

|Brand/Trade Names: |Half/Life: | | |

|Morphine |2-4 hours | | |

| | | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Severe pain. Pulmonary edema. Pain |Hypersensitivity. Some products contain |Onset: rapid |Instruct patient how and when to ask for pain medication |

|associated with MI. |tartrazine, bisulfites, or alcohol and should |Peak: 20 minutes |May cause drowsiness or dizziness |

| |be avoided in patients with known |Duration: 4-5 hours |Advise patient to change positions slowly to minimize orthostatic hypotension |

| |hypersensitivity. | |Caution patient to avoid concurrent use of alcohol or other CNS depressants |

| | | |Immobilized or bedrest patients to turn, cough, and breathe deeply every 2 hours to |

| | | |prevent atelectasis |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Binds to opiate receptors in the CNS. |Confusion, sedation, dizziness, dysphoria, | |Decrease in severity of pain without a significant alteration in level of consciousness |

|Alters the perception of and response |euphoria, hallucinations, headache, |IV (adults): 0.8-10 mg/hr may be |or respiratory status. |

|to painful stimuli while producing |respiratory depression, hypotension, |preceded by a bolus of 15 mg (infusion |Decrease in symptoms of pulmonary edema. |

|generalized CNS depression. |constipation, nausea, vomiting, sweating, |rates vary greatly up to 400 mg/hr have| |

| |itching, psychological dependence, tolerance |been used) | |

| | | | |

| | | | |

| | |Patient: 6 mg IVP | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Drug-Drug: Use with extreme caution in | |May increase plasma amylase and lipase levels |

|Decrease in severity of pain. |patients receiving MAO inhibitors within 14 | | |

| |days prior (may result in unpredictable, | | |

| |severe reactions- decrease initial dose of | | |

| |morphine to 25% of usual dose) | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Azithromycin |Agnets for atypical mycobacterium, |Mostly excreted unchanged in bile, 4.5%|Observe for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, |

| |anti-infectives, macrolides |excreted unchanged in urine |wheezing). Notify the physician or other health care professional immediately if these |

| | | |occur |

| | | |Assess patient for infections (vital signs, appearance of wound, sputum, urine, and |

| | | |stool, WBC) |

| | | |Obtain specimens for culture and sensitivity before initiating therapy |

|Brand/Trade Names: |Half/Life: | | |

|Zithromax |11-14 hour after single dose, 2-4 days after | | |

| |several doses, 59 hours after extended release| | |

| |suspension | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Treatment infections due to |Hypersensitivity to azithromycin, |Onset: rapid |Instruct patients to take medication as directed and to finish the drug completely |

|susceptible organisms |erythromycin, or other macrolide |Peak: 2.5-3.2 hours |Instruct patient not to take with food or antacids |

| |anti-infectives |Duration: 24 hours |May cause drowsiness or dizziness |

| | | |Advise patients to report symptoms of chest pain, palpitations, yellowing of the skin or|

| | | |eyes, or signs of superinfection |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Inhibits protein synthesis at the |Dizziness, seizures, drowsiness, | |Resolution of the signs and symptoms of infection. Length of time for complete |

|level of the 50S bacterial ribosome |pseudomembranous colitis, abdominal pain, |PO (adults): 500 mg once daily for 3 |resolution depends on the organism and site of infection |

| |diarrhea, nausea, angioedema |days | |

| | | | |

| | | | |

| | |Patient: 500 mg orally every day | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Drug-Drug: aluminum and magnesium-containing | |May cause increase serum bilirubin, AST, ALT, LDH, and alkaline phophatase |

|Bacteriostatic action against |antacids decrease peak serum levels. Digoxin, | |concentrations |

|susceptible bacteria |theophylline, ergotamine, dihydroergotaine, | |May cause increase in creatine phophokinase, potassium, prothrombin time, BUN, serum |

| |triazolam, carbamazepline, cycloporine, | |creatinine, and blood glucose concentrations |

| |tacrolimus and phenytoin are known to increase| |May occasionally cause decrease in WBC and platelet count |

| |serum levels & effects | | |

| | | | |

| | | | |

|Generic Drug Name: |Drug Classification: |Location of metabolism/excretion: |Nursing Implications/Assessment: |

|Acetaminophen |Antipyretics, nonopioid analgesics |85-95% metabolized by the liver. |Assess overall health status and alcohol usage before administration. |

| | |Metabolites may be toxic in overdose |Assess amount, frequency, and type of drugs taken in patients self-medicating, |

| | |situation. Metabolites excreted by the |especially with OTC drugs. |

| | |kidneys. |Pain: assess type, location, and intensity prior to and 30-60 minutes following |

| | | |administration |

|Brand/Trade Names: |Half/Life: | | |

|Tylenol |1-3 hours | | |

| | | | |

|Indications for use: |Contraindications: |Onset/Peak/Duration: |Key Patient Teaching Points: |

|Mild pain. Fever |Previous hypersensitivity. Products contain |Onset: 0.5-1 hour |Advise patient to take medication exactly as directed and not to take more than the |

| |alcohol, aspartame, saccharin, sugar, or |Peak: 1-3 hours |recommended amount. |

| |tartrazine should be avoided in patients who |Duration: 3-8 hours |Advise patient to avoid alcohol |

| |have hypersensitivity or intolerance to these | |Advise patient to consult health care professional if discomfort or fever is not |

| |compounds. | |relieved by routine doses of this drug or if fever is greater than 39.5 or lasts longer |

| | | |than 3 days |

|Action: |Adverse Reactions/Side Effects: |Routes and Dosage range for each route:|Evaluation criteria: |

|Inhibits the synthesis of |Hepatic failure, hepatotoxicity, renal | |Relief of mild pain |

|prostagladins that may serve as |failure, neutropenia, pancytopenia, |PO (adults): 325-650 mg every 4-6 hours|Reduction of fever |

|mediators of pain and fever, primarily|leukopenia, rash | | |

|in the CNS. Has no significant | | | |

|anti-inflammatory properties or GI | |Patient: 325 mg every 3 hours | |

|toxicity | | | |

|Therapeutic Effects: (expected |Interactions: | |Labs to monitor (if applicable): |

|outcome) |Chronic high-dose acetaminophen may increase | |Evaluate hepatic, hematologic, and renal function during prolonged, high-dose therapy |

|Analgesia. Antipyresis |the risk of bleeding with warfarin. | |May alter results of blood glucose monitoring |

| |Hepatotoxicity is additive with other | |Increased serum bilirubin, LDH, AST, ALT, and prothrombin time may indicate |

| |hepatotoxic substances including alcohol. | |hepatotoxicity |

| | | | |

| | | | |

| | | | |

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download